The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

The Philadelphia Citizen is recognizing CHOP doctors Alexis Thompson and Dr. Stephan Grupp with the 'Disruptors of the Year' ...

The Medical University of South Carolina Health has established the Rena N. Grant Sickle Cell Center to help treat those ...

Nearly a year after new sickle cell gene therapies were approved, CNBC's Bertha Coombs reports a small number of patients are starting to complete the months-long course of treatments, but the ...

Scott Turner Department of Housing and Urban Development secretary, announced a new Department of Government Efficiency Task ...

A SYSTEMATIC review by the American Society of Hematology (ASH) has found no evidence to support sickle cell trait (SCT) as a cause of acute pain crises or sudden exertion-related death. This finding ...

MUSC recieved updatesThe MUSC Board of Trustees received a key program update at the February board meeting on a ...

Deshawn "DJ" Chow is one of just over 100 sickle cell patients who have undergone treatment with new gene therapies. CVS Health CEO David Joyner said private insurers and employer-sponsored health ...

"Good Morning America" co-anchor Robin Roberts is marking 12 years since she returned to the anchor desk after receiving a ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.